Siponimod/Select Moderate CYP2C9 Inhibitors that Prolong QT Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may slow down how quickly your body processes siponimod.The first dose, and sometimes the second dose of siponimod slows your heart rate. Some medications also slow down the heart rate, or may not be safe if your heart rate is too slow.
What might happen:
The amount of siponimod in your body may increase and cause increased side effects. Your heart rate may go too low, or may become irregular.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Let your doctor know right away if you have any signs of an infection (fever; tiredness; body aches; chills; nausea; vomiting, or headache with fever, neck stiffness, light sensitivity, nausea, and/or confusion), changes in vision, irregular heartbeat, fainting, loss of appetite, breathing problems, or seizures.If these medications are used together, your doctor may monitor you in a medical facility for at least 6 to 24 hours after your first dose of siponimod to be sure you are safe. Let your doctor know right away if you notice an irregular heartbeat (palpitations) or have any dizziness, fainting episodes, fatigue or chest pain.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Mayzent (siponimod) US prescribing information. Novartis Pharmaceuticals Corporation June, 2022.
- 2.Mayzent (siponimod) UK summary of product characteristics. Novartis Pharmaceuticals UK Ltd January, 2021.
- 3.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 4.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.